These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
138 related items for PubMed ID: 19833248
1. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Hausdorff WP, Dagan R, Beckers F, Schuerman L. Vaccine; 2009 Dec 09; 27(52):7257-69. PubMed ID: 19833248 [Abstract] [Full Text] [Related]
2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. Pediatr Infect Dis J; 2009 Apr 09; 28(4 Suppl):S66-76. PubMed ID: 19325449 [Abstract] [Full Text] [Related]
3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Pediatr Infect Dis J; 2009 Apr 09; 28(4 Suppl):S77-88. PubMed ID: 19325450 [Abstract] [Full Text] [Related]
4. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L. Pediatr Infect Dis J; 2009 Apr 09; 28(4 Suppl):S89-96. PubMed ID: 19325451 [Abstract] [Full Text] [Related]
6. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Pediatr Infect Dis J; 2009 Apr 09; 28(4 Suppl):S97-S108. PubMed ID: 19325452 [Abstract] [Full Text] [Related]
11. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Dinleyici EC, Yargic ZA. Expert Rev Vaccines; 2008 Nov 09; 7(9):1367-94. PubMed ID: 18980540 [Abstract] [Full Text] [Related]
12. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R. Pediatr Infect Dis J; 2009 Apr 09; 28(4):277-82. PubMed ID: 19258924 [Abstract] [Full Text] [Related]
13. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, Macnair J, Pujar N, Manger W, Zhang Y, Antonello J, Shiver J, Caulfield M, Heinrichs JH. Vaccine; 2011 Nov 08; 29(48):8870-6. PubMed ID: 21964055 [Abstract] [Full Text] [Related]
15. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Dinleyici EC, Yargic ZA. Expert Rev Vaccines; 2009 Aug 08; 8(8):977-86. PubMed ID: 19627181 [Abstract] [Full Text] [Related]
16. Prevenar vaccination: review of the global data, 2006. Center KJ. Vaccine; 2007 Apr 20; 25(16):3085-9. PubMed ID: 17287048 [Abstract] [Full Text] [Related]
17. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Izurieta P, Nieto Guevara J. Hum Vaccin Immunother; 2022 Dec 31; 18(1):1872341. PubMed ID: 33605846 [Abstract] [Full Text] [Related]